SI-BONE Inc. Releases Presentation Highlighting Strong Q2 2025 Financial Performance and Continued Growth
SI-BONE Inc. has released its August 2025 Investor Presentation, showcasing a strong Q2 2025 performance with a 21.7% increase in worldwide revenue to $48.6 million and a 22.8% rise in U.S. revenue to $46.4 million. Key highlights include the launch of iFuse TORQ in Europe, a 25.0% growth in U.S. active physicians, an 80 basis point improvement in gross margin to 79.8%, and a positive adjusted EBITDA of $1.0 million. The company also generated $1.1 million in net cash.
SI-BONE Inc. has released its August 2025 Investor Presentation, highlighting key financial and operational achievements in the second quarter of 2025. The company reported a 21.7% growth in worldwide revenue, reaching $48.6 million, and a 22.8% increase in U.S. revenue totaling $46.4 million. Notable developments include the launch of iFuse TORQ in Europe and a 25.0% growth in U.S. active physicians. The gross margin improved by 80 basis points to 79.8%, and the company achieved $1.0 million in positive adjusted EBITDA. Additionally, net cash generation amounted to $1.1 million. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SI-BONE Inc. published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
